NY-TRG/AMCE
16.7.2021 00:16:13 CEST | Business Wire | Press release
The Rohatyn Group (“TRG”), a global, US-based asset management firm with expertise in emerging markets and real assets, and A&M Capital Europe (“AMCE”), a London-based, operationally-focused European middle-market private equity firm, today announced that they have entered into a definitive agreement under which TRG will sell Pet Network International d.o.o. (“Pet Network” or “the Company”) to AMCE. Pet Network is the leading omni channel pet care platform in southeast Europe, operating across Croatia, Romania, Slovenia, Serbia and Bulgaria. The transaction, terms of which were not disclosed, is expected to close in the third quarter of 2021.
Pet Network was created by TRG in 2018 through the acquisition and merger of three distinct businesses active in the pet supplies industry across southeast Europe: Pet Centar, which operates in Croatia, Serbia and Romania; Animax, which operates in Romania; and Mr. Pet, which operates in Slovenia. The origins of the group date back to 1999 when the first Pet Centar store was opened in Croatia. Today the Company operates more than 150 physical stores across five countries under the Pet Centar, Maxi Pet, Animax and Mr. Pet brands. The Company also operates various eCommerce channels as well as a growing offering of value-added services including veterinary pharmacies.
TRG Managing Directors Stepan Karpukhin and Harold Chatelus commented: “Pet Network is a fast growing and highly successful business that has benefitted from the global trends around pet humanization, combined with high levels of pet ownership across southeast Europe. The Company’s talented management team, led by CEO Ljiljana Markov Medugorac, has played a vital role in capitalizing on this positive momentum and will continue to run the business post the transaction closing.”
Colin Clark, Head of EMEA at TRG, added: “In line with TRG’s buy-and-build philosophy, during our ownership period, Pet Network has delivered remarkable growth and transformed into a sizeable business on a European scale. We are confident that AMCE is the right partner for Pet Network’s next chapter and are pleased to have found a like-minded investor to further the Company’s growth story.”
Ljiljana Markov Medugorac, CEO of Pet Network International commented: “TRG’s acquisition three years ago was an important milestone that helped us achieve rapid growth, add-on acquisitions, many new store openings, online expansion, an expanded own brands portfolio and countless other initiatives. Navigating through a global pandemic over the past year, we also expanded our operations to a new exciting market, Bulgaria. We are all proud of Pet Network's teams achievements, which were strongly backed up with TRG's support and guidance. While we will be sad to say goodbye to our colleagues at TRG, we are also excited to start the next chapter in the company’s development in partnership with AMCE, who like TRG share our vision for the company’s future growth.”
TRG CEO Nick Rohatyn added, “We are proud of our investment in Pet Network. This represents a landmark transaction for the European team as well as TRG globally. Given the strong growth drivers underpinning the pet space, TRG views this as a highly attractive sector. Our experience with Pet Network represents a great example of the innovative consumer focused businesses that can benefit from consolidation and pan-European scale that we like at TRG.”
TRG was advised on the transaction by William Blair (M&A), Deloitte (Financial & Tax), Baker McKenzie (Legal), Babic (Legal) and BCG (Commercial).
AMCE was advised by Houlihan Lokey and Alantra (M&A), Alvarez & Marsal (operations), Dickson Minto (Legal), EY (Financial & Tax), AT Kearney (Commercial).
About TRG
Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets headquartered in New York, with a presence around the globe including Boston, Buenos Aires, Montevideo, Lima, São Paulo, London, Cairo, Mumbai, New Delhi, Singapore, Hanoi, Kuala Lumpur and Rotorua. For more information, please visit www.rohatyngroup.com
About AMCE
AMCE is a London based, operationally growth focused European middle-market private equity firm. AMCE Fund I currently manages €650 million of committed capital and is part of A&M Capital, the global multi-strategy private equity firm managing in excess of €3 billion of capital. AMCE has an association with Alvarez & Marsal consulting (“A&M”) that enables AMCE to access the world class operational expertise of A&M’s almost 4,500 consultants across A&M’s 23 European offices and 65 offices globally. For more information, please visit www.a-mcapital.com/europe/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715006085/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
